| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | extracellular matrix structural constituent | 8.32e-04 | 188 | 20 | 3 | GO:0005201 | |
| GeneOntologyMolecularFunction | nuclear receptor activity | 1.63e-03 | 60 | 20 | 2 | GO:0004879 | |
| GeneOntologyMolecularFunction | ligand-activated transcription factor activity | 1.68e-03 | 61 | 20 | 2 | GO:0098531 | |
| GeneOntologyBiologicalProcess | positive regulation of response to nutrient levels | 2.49e-05 | 8 | 20 | 2 | GO:0032109 | |
| GeneOntologyBiologicalProcess | response to lipid | 5.86e-05 | 1126 | 20 | 7 | GO:0033993 | |
| GeneOntologyBiologicalProcess | response to peptide hormone | 1.24e-04 | 530 | 20 | 5 | GO:0043434 | |
| GeneOntologyBiologicalProcess | developmental cell growth | 1.79e-04 | 301 | 20 | 4 | GO:0048588 | |
| GeneOntologyBiologicalProcess | toll-like receptor 9 signaling pathway | 2.23e-04 | 23 | 20 | 2 | GO:0034162 | |
| GeneOntologyBiologicalProcess | cell growth | 2.67e-04 | 625 | 20 | 5 | GO:0016049 | |
| GeneOntologyBiologicalProcess | glucose homeostasis | 2.79e-04 | 338 | 20 | 4 | GO:0042593 | |
| GeneOntologyBiologicalProcess | carbohydrate homeostasis | 2.82e-04 | 339 | 20 | 4 | GO:0033500 | |
| GeneOntologyBiologicalProcess | cellular response to oxygen-containing compound | 2.87e-04 | 1450 | 20 | 7 | GO:1901701 | |
| GeneOntologyBiologicalProcess | negative regulation of multicellular organismal process | 3.37e-04 | 1488 | 20 | 7 | GO:0051241 | |
| GeneOntologyBiologicalProcess | response to hormone | 3.44e-04 | 1042 | 20 | 6 | GO:0009725 | |
| GeneOntologyBiologicalProcess | positive regulation of transport | 4.20e-04 | 1081 | 20 | 6 | GO:0051050 | |
| GeneOntologyBiologicalProcess | cellular response to peptide hormone stimulus | 4.39e-04 | 381 | 20 | 4 | GO:0071375 | |
| GeneOntologyBiologicalProcess | cellular response to hormone stimulus | 5.35e-04 | 727 | 20 | 5 | GO:0032870 | |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 6.12e-04 | 416 | 20 | 4 | GO:0030522 | |
| GeneOntologyBiologicalProcess | cellular response to nitrogen compound | 6.24e-04 | 752 | 20 | 5 | GO:1901699 | |
| GeneOntologyBiologicalProcess | developmental process involved in reproduction | 8.52e-04 | 1235 | 20 | 6 | GO:0003006 | |
| GeneOntologyBiologicalProcess | growth | 8.52e-04 | 1235 | 20 | 6 | GO:0040007 | |
| GeneOntologyBiologicalProcess | regulation of response to nutrient levels | 9.01e-04 | 46 | 20 | 2 | GO:0032107 | |
| GeneOntologyBiologicalProcess | negative regulation of cold-induced thermogenesis | 9.81e-04 | 48 | 20 | 2 | GO:0120163 | |
| GeneOntologyBiologicalProcess | response to nitrogen compound | 9.95e-04 | 1272 | 20 | 6 | GO:1901698 | |
| GeneOntologyBiologicalProcess | regulation of interleukin-6 production | 1.07e-03 | 212 | 20 | 3 | GO:0032675 | |
| GeneOntologyBiologicalProcess | interleukin-6 production | 1.21e-03 | 221 | 20 | 3 | GO:0032635 | |
| GeneOntologyBiologicalProcess | cellular response to nutrient | 1.29e-03 | 55 | 20 | 2 | GO:0031670 | |
| GeneOntologyBiologicalProcess | endolysosomal toll-like receptor signaling pathway | 1.33e-03 | 56 | 20 | 2 | GO:0140894 | |
| GeneOntologyBiologicalProcess | developmental growth | 1.48e-03 | 911 | 20 | 5 | GO:0048589 | |
| GeneOntologyBiologicalProcess | negative regulation of inflammatory response | 1.51e-03 | 239 | 20 | 3 | GO:0050728 | |
| GeneOntologyCellularComponent | microfibril | 7.45e-05 | 13 | 21 | 2 | GO:0001527 | |
| HumanPheno | Enlarged polycystic ovaries | 2.11e-06 | 16 | 9 | 3 | HP:0008675 | |
| HumanPheno | Enlarged ovaries | 3.07e-06 | 18 | 9 | 3 | HP:0100879 | |
| HumanPheno | Neoplasm of the eye | 6.75e-05 | 49 | 9 | 3 | HP:0100012 | |
| MousePheno | decreased body fat mass | 1.81e-05 | 46 | 16 | 3 | MP:0014143 | |
| MousePheno | abnormal susceptibility to weight gain | 1.83e-05 | 309 | 16 | 5 | MP:0011117 | |
| MousePheno | abnormal white adipose tissue morphology | 2.20e-05 | 321 | 16 | 5 | MP:0002970 | |
| MousePheno | decreased susceptibility to weight gain | 4.87e-05 | 186 | 16 | 4 | MP:0010182 | |
| MousePheno | increased energy expenditure | 5.98e-05 | 196 | 16 | 4 | MP:0004889 | |
| MousePheno | abnormal uterus morphology | 7.50e-05 | 415 | 16 | 5 | MP:0001120 | |
| MousePheno | abnormal salivary gland morphology | 8.55e-05 | 77 | 16 | 3 | MP:0000613 | |
| MousePheno | increased granulosa cell apoptosis | 9.51e-05 | 13 | 16 | 2 | MP:0013508 | |
| MousePheno | abnormal body fat mass | 1.03e-04 | 82 | 16 | 3 | MP:0012320 | |
| MousePheno | abnormal granulosa cell apoptosis | 1.28e-04 | 15 | 16 | 2 | MP:0031015 | |
| MousePheno | small uterus | 1.45e-04 | 92 | 16 | 3 | MP:0002637 | |
| MousePheno | abnormal merocrine gland morphology | 1.70e-04 | 97 | 16 | 3 | MP:0013544 | |
| MousePheno | increased bile salt level | 2.31e-04 | 20 | 16 | 2 | MP:0004789 | |
| MousePheno | increased ovary apoptosis | 2.31e-04 | 20 | 16 | 2 | MP:0013507 | |
| MousePheno | increased liver adenoma incidence | 2.31e-04 | 20 | 16 | 2 | MP:0003324 | |
| MousePheno | abnormal adenoma incidence | 2.46e-04 | 110 | 16 | 3 | MP:0020189 | |
| MousePheno | increased adenoma incidence | 2.46e-04 | 110 | 16 | 3 | MP:0010383 | |
| MousePheno | embryonic lethality during organogenesis | 2.77e-04 | 876 | 16 | 6 | MP:0006207 | |
| MousePheno | abnormal ovary apoptosis | 2.80e-04 | 22 | 16 | 2 | MP:0013506 | |
| MousePheno | increased anti-nuclear antigen antibody level | 2.81e-04 | 115 | 16 | 3 | MP:0004794 | |
| MousePheno | abnormal inflammatory response | 3.34e-04 | 1310 | 16 | 7 | MP:0001845 | |
| MousePheno | abnormal energy expenditure | 3.63e-04 | 313 | 16 | 4 | MP:0005450 | |
| MousePheno | abnormal ovulation cycle | 3.67e-04 | 126 | 16 | 3 | MP:0009344 | |
| MousePheno | abnormal pericardial cavity morphology | 3.85e-04 | 128 | 16 | 3 | MP:0012501 | |
| MousePheno | abnormal energy homeostasis | 4.04e-04 | 322 | 16 | 4 | MP:0005448 | |
| MousePheno | abnormal adipose tissue morphology | 4.23e-04 | 1361 | 16 | 7 | MP:0000003 | |
| MousePheno | increased autoantibody level | 4.31e-04 | 133 | 16 | 3 | MP:0003725 | |
| MousePheno | adipose tissue phenotype | 4.68e-04 | 1383 | 16 | 7 | MP:0005375 | |
| MousePheno | vascular inflammation | 4.90e-04 | 29 | 16 | 2 | MP:0001864 | |
| MousePheno | abnormal bile salt level | 6.35e-04 | 33 | 16 | 2 | MP:0004774 | |
| MousePheno | decreased susceptibility to diet-induced obesity | 7.39e-04 | 160 | 16 | 3 | MP:0005659 | |
| MousePheno | abnormal gland physiology | 8.05e-04 | 691 | 16 | 5 | MP:0002164 | |
| MousePheno | increased inflammatory response | 8.42e-04 | 1077 | 16 | 6 | MP:0001846 | |
| MousePheno | decreased circulating estradiol level | 8.43e-04 | 38 | 16 | 2 | MP:0005181 | |
| MousePheno | increased mature B cell number | 8.51e-04 | 168 | 16 | 3 | MP:0008210 | |
| MousePheno | abnormal uterus size | 8.51e-04 | 168 | 16 | 3 | MP:0004902 | |
| MousePheno | embryonic lethality during organogenesis, complete penetrance | 8.54e-04 | 700 | 16 | 5 | MP:0011098 | |
| MousePheno | decreased radius size | 9.34e-04 | 40 | 16 | 2 | MP:0030886 | |
| MousePheno | short radius | 9.34e-04 | 40 | 16 | 2 | MP:0004355 | |
| MousePheno | decreased circulating estrogen level | 9.81e-04 | 41 | 16 | 2 | MP:0003371 | |
| MousePheno | abnormal internal female genitalia morphology | 1.22e-03 | 757 | 16 | 5 | MP:0009209 | |
| MousePheno | short ulna | 1.23e-03 | 46 | 16 | 2 | MP:0004359 | |
| MousePheno | decreased ulna size | 1.23e-03 | 46 | 16 | 2 | MP:0030900 | |
| MousePheno | abnormal female genitalia morphology | 1.26e-03 | 763 | 16 | 5 | MP:0009208 | |
| MousePheno | abnormal female reproductive system morphology | 1.28e-03 | 766 | 16 | 5 | MP:0001119 | |
| MousePheno | abnormal bile salt homeostasis | 1.29e-03 | 47 | 16 | 2 | MP:0005365 | |
| MousePheno | decreased bone mineral density of femur | 1.29e-03 | 47 | 16 | 2 | MP:0020010 | |
| MousePheno | abnormal exocrine gland physiology | 1.33e-03 | 196 | 16 | 3 | MP:0013559 | |
| MousePheno | increased carcinoma incidence | 1.35e-03 | 197 | 16 | 3 | MP:0002038 | |
| MousePheno | dilated heart atrium | 1.40e-03 | 49 | 16 | 2 | MP:0003140 | |
| MousePheno | abnormal glucose tolerance | 1.45e-03 | 787 | 16 | 5 | MP:0005291 | |
| MousePheno | abnormal circulating estradiol level | 1.58e-03 | 52 | 16 | 2 | MP:0005183 | |
| MousePheno | multinucleated giant male germ cells | 1.64e-03 | 53 | 16 | 2 | MP:0020550 | |
| MousePheno | abnormal heart atrium size | 1.70e-03 | 54 | 16 | 2 | MP:0031576 | |
| MousePheno | abnormal female reproductive gland morphology | 1.73e-03 | 475 | 16 | 4 | MP:0013324 | |
| MousePheno | decreased bone mineral density | 1.74e-03 | 476 | 16 | 4 | MP:0000063 | |
| MousePheno | impaired glucose tolerance | 1.80e-03 | 480 | 16 | 4 | MP:0005293 | |
| MousePheno | abnormal circulating estrogen level | 1.89e-03 | 57 | 16 | 2 | MP:0003369 | |
| MousePheno | reduced fertility | 1.98e-03 | 844 | 16 | 5 | MP:0001921 | |
| MousePheno | abnormal exocrine gland morphology | 2.07e-03 | 853 | 16 | 5 | MP:0013558 | |
| MousePheno | abnormal liver lobule morphology | 2.08e-03 | 229 | 16 | 3 | MP:0008987 | |
| MousePheno | increased dendritic cell number | 2.09e-03 | 60 | 16 | 2 | MP:0008126 | |
| MousePheno | impaired ovarian folliculogenesis | 2.16e-03 | 61 | 16 | 2 | MP:0001129 | |
| MousePheno | enlarged spleen | 2.17e-03 | 862 | 16 | 5 | MP:0000691 | |
| MousePheno | increased malignant tumor incidence | 2.29e-03 | 237 | 16 | 3 | MP:0002018 | |
| MousePheno | abnormal bone mineral density of femur | 2.30e-03 | 63 | 16 | 2 | MP:0020009 | |
| Domain | FBN | 3.61e-06 | 3 | 21 | 2 | IPR011398 | |
| Domain | TB | 2.52e-05 | 7 | 21 | 2 | PF00683 | |
| Domain | - | 3.36e-05 | 8 | 21 | 2 | 3.90.290.10 | |
| Domain | TB | 4.31e-05 | 9 | 21 | 2 | PS51364 | |
| Domain | TB_dom | 4.31e-05 | 9 | 21 | 2 | IPR017878 | |
| Domain | VitD_rcpt | 1.09e-04 | 14 | 21 | 2 | IPR000324 | |
| Domain | cEGF | 3.85e-04 | 26 | 21 | 2 | IPR026823 | |
| Domain | cEGF | 3.85e-04 | 26 | 21 | 2 | PF12662 | |
| Domain | zf-C4 | 1.21e-03 | 46 | 21 | 2 | PF00105 | |
| Domain | NUCLEAR_REC_DBD_1 | 1.21e-03 | 46 | 21 | 2 | PS00031 | |
| Domain | Znf_hrmn_rcpt | 1.21e-03 | 46 | 21 | 2 | IPR001628 | |
| Domain | Nuclear_hrmn_rcpt | 1.21e-03 | 46 | 21 | 2 | IPR001723 | |
| Domain | ZnF_C4 | 1.21e-03 | 46 | 21 | 2 | SM00399 | |
| Domain | NUCLEAR_REC_DBD_2 | 1.21e-03 | 46 | 21 | 2 | PS51030 | |
| Domain | - | 1.26e-03 | 47 | 21 | 2 | 1.10.565.10 | |
| Domain | HOLI | 1.32e-03 | 48 | 21 | 2 | SM00430 | |
| Domain | Nucl_hrmn_rcpt_lig-bd | 1.32e-03 | 48 | 21 | 2 | IPR000536 | |
| Domain | Hormone_recep | 1.32e-03 | 48 | 21 | 2 | PF00104 | |
| Domain | - | 1.85e-03 | 57 | 21 | 2 | 3.30.50.10 | |
| Domain | Znf_NHR/GATA | 1.92e-03 | 58 | 21 | 2 | IPR013088 | |
| Domain | Ank | 2.03e-03 | 228 | 21 | 3 | PF00023 | |
| Domain | ANK | 2.67e-03 | 251 | 21 | 3 | SM00248 | |
| Domain | ANK_REPEAT | 2.73e-03 | 253 | 21 | 3 | PS50088 | |
| Domain | ANK_REP_REGION | 2.76e-03 | 254 | 21 | 3 | PS50297 | |
| Domain | Ankyrin_rpt | 3.01e-03 | 262 | 21 | 3 | IPR002110 | |
| Domain | EGF_CA | 4.16e-03 | 86 | 21 | 2 | PF07645 | |
| Domain | EGF_Ca-bd_CS | 5.26e-03 | 97 | 21 | 2 | IPR018097 | |
| Domain | EGF_CA | 5.47e-03 | 99 | 21 | 2 | PS01187 | |
| Domain | ASX_HYDROXYL | 5.58e-03 | 100 | 21 | 2 | PS00010 | |
| Domain | EGF-type_Asp/Asn_hydroxyl_site | 6.25e-03 | 106 | 21 | 2 | IPR000152 | |
| Domain | EGF_CA | 8.19e-03 | 122 | 21 | 2 | SM00179 | |
| Domain | EGF-like_Ca-bd_dom | 8.45e-03 | 124 | 21 | 2 | IPR001881 | |
| Domain | Growth_fac_rcpt_ | 1.31e-02 | 156 | 21 | 2 | IPR009030 | |
| Pathway | WP_HYPOTHESIZED_PATHWAYS_IN_PATHOGENESIS_OF_CARDIOVASCULAR_DISEASE | 2.31e-08 | 25 | 18 | 4 | M39713 | |
| Pubmed | 3.47e-07 | 2 | 21 | 2 | 24037887 | ||
| Pubmed | 3.47e-07 | 2 | 21 | 2 | 15221638 | ||
| Pubmed | 1.04e-06 | 3 | 21 | 2 | 35073341 | ||
| Pubmed | 1.04e-06 | 3 | 21 | 2 | 34724040 | ||
| Pubmed | 1.04e-06 | 3 | 21 | 2 | 20026603 | ||
| Pubmed | 1.04e-06 | 3 | 21 | 2 | 22265968 | ||
| Pubmed | Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice. | 1.04e-06 | 3 | 21 | 2 | 33924999 | |
| Pubmed | 2.08e-06 | 4 | 21 | 2 | 32581266 | ||
| Pubmed | Heparin/heparan sulfate controls fibrillin-1, -2 and -3 self-interactions in microfibril assembly. | 2.08e-06 | 4 | 21 | 2 | 25034023 | |
| Pubmed | Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. | 3.47e-06 | 5 | 21 | 2 | 29610476 | |
| Pubmed | Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. | 3.47e-06 | 5 | 21 | 2 | 24953650 | |
| Pubmed | ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. | 5.44e-06 | 57 | 21 | 3 | 23788249 | |
| Pubmed | 7.28e-06 | 7 | 21 | 2 | 19556342 | ||
| Pubmed | 7.28e-06 | 7 | 21 | 2 | 24323028 | ||
| Pubmed | 9.70e-06 | 8 | 21 | 2 | 12475935 | ||
| Pubmed | Modelling bladder cancer in mice: opportunities and challenges. | 2.70e-05 | 13 | 21 | 2 | 25533675 | |
| Pubmed | 8.72e-05 | 23 | 21 | 2 | 29567669 | ||
| Pubmed | Family-based analysis of candidate genes for polycystic ovary syndrome. | 1.21e-04 | 27 | 21 | 2 | 20200332 | |
| Pubmed | 1.21e-04 | 27 | 21 | 2 | 35894043 | ||
| Pubmed | 1.40e-04 | 29 | 21 | 2 | 34461288 | ||
| Pubmed | STK11 is required for the normal program of ciliated cell differentiation in airways. | 1.60e-04 | 31 | 21 | 2 | 31636950 | |
| Pubmed | Genetic variations strongly influence phenotypic outcome in the mouse retina. | 3.54e-04 | 46 | 21 | 2 | 21779340 | |
| Pubmed | 3.54e-04 | 46 | 21 | 2 | 20301533 | ||
| Pubmed | 5.62e-04 | 58 | 21 | 2 | 25142465 | ||
| Interaction | POTED interactions | 6.20e-06 | 4 | 21 | 2 | int:POTED | |
| Interaction | RXRB interactions | 4.28e-05 | 66 | 21 | 3 | int:RXRB | |
| Interaction | KDM5A interactions | 6.03e-05 | 74 | 21 | 3 | int:KDM5A | |
| Interaction | POTEC interactions | 8.01e-05 | 13 | 21 | 2 | int:POTEC | |
| Interaction | PAX2 interactions | 9.12e-05 | 85 | 21 | 3 | int:PAX2 | |
| Cytoband | 15q21.1 | 1.31e-04 | 37 | 21 | 2 | 15q21.1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr15q21 | 2.96e-03 | 177 | 21 | 2 | chr15q21 | |
| GeneFamily | Ankyrin repeat domain containing|POTE ankyrin domain containing | 5.69e-05 | 13 | 16 | 2 | 685 | |
| GeneFamily | Nuclear hormone receptors | 8.43e-04 | 49 | 16 | 2 | 71 | |
| GeneFamily | Ankyrin repeat domain containing | 1.17e-03 | 242 | 16 | 3 | 403 | |
| Coexpression | NABA_MATRISOME_INSULINOMA | 1.28e-05 | 7 | 21 | 2 | MM17050 | |
| Coexpression | DING_LUNG_CANCER_MUTATED_FREQUENTLY | 4.02e-05 | 12 | 21 | 2 | M16718 | |
| Coexpression | ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_DN | 4.20e-05 | 85 | 21 | 3 | M41085 | |
| ToppCell | Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Inmt_(Inmt)-|Posterior_cortex / BrainAtlas - Mouse McCarroll V32 | 2.11e-07 | 112 | 21 | 4 | ba0bd3a77c4865a71fb92d195cd7459c562b63db | |
| ToppCell | Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1|Posterior_cortex / BrainAtlas - Mouse McCarroll V32 | 2.11e-07 | 112 | 21 | 4 | f9a796b4b5e227096ab360ca9ec08b1c564ac1eb | |
| ToppCell | Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Inmt_(Inmt)|Posterior_cortex / BrainAtlas - Mouse McCarroll V32 | 2.11e-07 | 112 | 21 | 4 | 153614f307525af56501ac8f9c357c5f7de7882c | |
| ToppCell | Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Posterior_cortex / BrainAtlas - Mouse McCarroll V32 | 2.56e-05 | 123 | 21 | 3 | 28be15b759c152662b29c323b1cc3f02f7830dbe | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.30e-05 | 134 | 21 | 3 | b959899c89d3a0363a3cd2309155280e0fe5ba88 | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 5.50e-05 | 159 | 21 | 3 | 92049a8d8fc9997d8d0d76500c72596a9b2394e0 | |
| ToppCell | PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 6.59e-05 | 169 | 21 | 3 | 031465190cd3623a25ef2b868daab8d932c8ff08 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.70e-05 | 170 | 21 | 3 | 5570c0e825bca77613bf0ebde620cf744fa1cb84 | |
| ToppCell | NS-moderate-d_16-33-Lymphoid-NK|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.21e-05 | 182 | 21 | 3 | fb503f8ecd013f1f2161a5841572b57cfcddb6fa | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.34e-05 | 183 | 21 | 3 | 8a799807fbf24456a9811e0c64068187940a2f71 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.48e-05 | 184 | 21 | 3 | 102b6f621a5b551e622f97b12d787c080b052a72 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.47e-05 | 191 | 21 | 3 | 75d2197076a9dfc868e8baf95bd4c5e44f438e3e | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.47e-05 | 191 | 21 | 3 | 4b50fdd310701251e64e16cd2d07ce03dbfd3e3e | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.62e-05 | 192 | 21 | 3 | ad48c941a3ddfd9a5146bafc2209da577bb50531 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.62e-05 | 192 | 21 | 3 | 19b94f254d51b9bda3d9b7c6f85e27ecb58409c8 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal-Dividing_Basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.01e-04 | 195 | 21 | 3 | 5812b1615676f3b77eb4769216b98b360c417c0d | |
| ToppCell | COVID-19_Mild-Classical_Monocyte-cMono_3|COVID-19_Mild / Disease condition and Cell class | 1.02e-04 | 196 | 21 | 3 | f245e929a286cb097130572e1027b4f01be8b04d | |
| ToppCell | COVID-19_Mild-Classical_Monocyte-cMono_3|Classical_Monocyte / Disease condition and Cell class | 1.02e-04 | 196 | 21 | 3 | 15397ec27167bb2fb6fec120b68bf38fc71b2670 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-1m-Mesenchymal-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 198 | 21 | 3 | 5e70246a9ce199cb2fb5379912b8ab59456219e4 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-1m-Mesenchymal|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 198 | 21 | 3 | b086af292a508a156266c2d899ba1caf820bf61c | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-1m-Mesenchymal-mesenchymal_stem_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-04 | 198 | 21 | 3 | 1b90d632e59c3c47b936e829cceeb0334f05f34f | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_adipo-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.07e-04 | 199 | 21 | 3 | 9b2262edbdec89166d895ab97527e0ee5f9b6010 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_adipo|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.07e-04 | 199 | 21 | 3 | 251b3643dcd8f4645b17101bd716e66f12a20e88 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_adipo-stroma-adipo-CAR|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.07e-04 | 199 | 21 | 3 | 117f4f43b6c06dda553799b1063e827bce697370 | |
| ToppCell | ILEUM-inflamed-(8)_Activated_fibroblasts|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.07e-04 | 199 | 21 | 3 | 317f412996d463ddf2e6a52ff41d5d676c77f43f | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.08e-04 | 200 | 21 | 3 | e663995fc44c340d878d66b278b7b5c2ff784301 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.08e-04 | 200 | 21 | 3 | 2cb8a39a12522a9643c6244d5e94cb4559868bb9 | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-3|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 1.08e-04 | 200 | 21 | 3 | 8cc5057b0e5ae9b72ea40d2ffbc52b79bf87ccef | |
| ToppCell | tumor_Lymph_Node_/_Brain-Fibroblasts-Myofibroblasts|Fibroblasts / Location, Cell class and cell subclass | 1.08e-04 | 200 | 21 | 3 | eabb7d4aa92ace7d970bcd3fae2c7cb5400a43b4 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | d2fcd3bd7c3223875f027eeb48ff621192a5f242 | |
| ToppCell | LPS_IL1RA-Mesenchymal_myocytic-Pericyte-Pericyte_2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.08e-04 | 200 | 21 | 3 | cf883ba5dbe6350b93142d625a52b25ff2a8bb63 | |
| ToppCell | tumor_Lymph_Node_/_Brain-Fibroblasts-Myofibroblasts|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 1.08e-04 | 200 | 21 | 3 | ca777a7d001848f6d01c613ff2bda7e4f3e20521 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 4.92e-04 | 70 | 21 | 2 | 6b706d0b6b7565ba7d6b169c6b49497e510de68b | |
| ToppCell | 356C-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 4.92e-04 | 70 | 21 | 2 | 8e1c2442e89ed54603905472daa11ec23238ffb0 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Conventional_Leiomyosarcoma-3|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 8.65e-04 | 93 | 21 | 2 | be5bd6d0a1d23c9aca6436c247ed173d009e7623 | |
| ToppCell | Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)-|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.79e-04 | 99 | 21 | 2 | 98c40a27432929434879c9e7283a14102f405f39 | |
| ToppCell | Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 9.79e-04 | 99 | 21 | 2 | d6bd8075dc7aba2034ea78b1389868282bc80a2d | |
| ToppCell | TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Fibrolamellar|TCGA-Liver / Sample_Type by Project: Shred V9 | 1.04e-03 | 102 | 21 | 2 | 070b3da7a22d635746e898773700ded4f92e94bb | |
| ToppCell | TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Fibrolamellar-6|TCGA-Liver / Sample_Type by Project: Shred V9 | 1.04e-03 | 102 | 21 | 2 | 106e25bc79163fcb4c5b4202e32c5ea1d2e44588 | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Il33_(Il33)-|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.14e-03 | 107 | 21 | 2 | d446ffbe93cd49669f1cf91411aae07cc15d9e2a | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Il33_(Il33)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.14e-03 | 107 | 21 | 2 | 5c9e745d0b08a4aa1f3a93f9cc094fac57061a30 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.25e-03 | 112 | 21 | 2 | 88fcd0dc12b5c00804381fb7dd59a6a2a9f37419 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)-|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.25e-03 | 112 | 21 | 2 | fd4cc5190626cb262aae0a7f04559b0e9757270e | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.25e-03 | 112 | 21 | 2 | d652e6fae433a6b56bf2a448fba2cf6c5e558905 | |
| ToppCell | Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)-|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 1.39e-03 | 118 | 21 | 2 | 3cebd17f4688cd43fe1283dc60957e87d5536810 | |
| ToppCell | Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Rgs5Acta2.Kcnj8_(Mural.Rgs5Acta2.Kcnj8)|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 1.39e-03 | 118 | 21 | 2 | 71f63efc641cd07c870f7695118fb244929c1536 | |
| ToppCell | Entopeduncular-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 1.39e-03 | 118 | 21 | 2 | 61b00b001edb1954a5fffaf4dfe71708124a45e5 | |
| ToppCell | COVID-19-kidney-Mito-rich_Int|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.48e-03 | 122 | 21 | 2 | a4220adb4e6055a599bd9bbf65d460fc4e68b543 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)-|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.78e-03 | 134 | 21 | 2 | a3547a68012d879d4dfe80394eace70808722e43 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells-iNKT-MAIT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.78e-03 | 134 | 21 | 2 | 92981dc68c1b3cdc53f9cf83386c47f0c6c98ae7 | |
| ToppCell | Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)|Striatum / BrainAtlas - Mouse McCarroll V32 | 1.78e-03 | 134 | 21 | 2 | 9458e2d0dbc18d9025b66b59f3ecc2fbc5384940 | |
| ToppCell | PND07-28-samps-Lymphocyte-B_cell-B_cell_2|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 1.86e-03 | 137 | 21 | 2 | 2544d1256f11da6e3bad24a871b2253e0ab20d01 | |
| ToppCell | PND07-28-samps-Lymphocyte-B_cell|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 1.86e-03 | 137 | 21 | 2 | 874e2eaa7846a2832f46b77c726d79f220a4a1cd | |
| ToppCell | RV-14._Fibroblast_III|RV / Chamber and Cluster_Paper | 1.94e-03 | 140 | 21 | 2 | b4fee8eb6bf855b364b00bda3f78e49d851bbca0 | |
| ToppCell | LPS-antiTNF-Endothelial-Epi-like|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.05e-03 | 144 | 21 | 2 | 75b16adfbe84f69376e6566d531ba7919d5c5192 | |
| ToppCell | 368C-Myeloid-Macrophage-FABP4+_Macrophage|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 2.11e-03 | 146 | 21 | 2 | 5b2608b56204dda9a773988f42ff00a9fa743a39 | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 2.14e-03 | 147 | 21 | 2 | 94998bc40f5c08295cfe3bdcbe43f13b1e564b3d | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.20e-03 | 149 | 21 | 2 | aedbae2dffa1e880e5c6a146b6d5a135e7f54308 | |
| ToppCell | TCGA-Breast-Metastatic-Breast_Carcinoma-Infiltrating_Ductal_Carcinoma|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.20e-03 | 149 | 21 | 2 | 2e9b898f3df22f8e872f2c278eff454c39e55b3b | |
| ToppCell | TCGA-Breast-Metastatic|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.20e-03 | 149 | 21 | 2 | 144ac2c458209ce510674bc2f83eb4c8e4d3c953 | |
| ToppCell | TCGA-Breast-Metastatic-Breast_Carcinoma|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.20e-03 | 149 | 21 | 2 | c7dc495141cd921b6b6f291a68851b7b807d0d0a | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Ductal_and_Lobular_Carcinoma-6|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.20e-03 | 149 | 21 | 2 | 3904f8ce9078de238600ceceee0116af52256a1c | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.22e-03 | 150 | 21 | 2 | 8645b9c7f9511ed6cc9afe04440c2873a3094150 | |
| ToppCell | facs-Aorta-Heart-3m-Mesenchymal-valve_cells|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 153 | 21 | 2 | 1440f2716fea74e2c3eb2924eba3d63ebd08c997 | |
| ToppCell | PND28-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD4_T-CD4_T_prolif|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.31e-03 | 153 | 21 | 2 | 5ac4b97d35c1029a5fc625239f92e35136c4d832 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L6_LAMP5_ANKRD20A11P|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.37e-03 | 155 | 21 | 2 | b782a835cf6e98befa16b560f3f2c9fde0c24045 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia_independent-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.40e-03 | 156 | 21 | 2 | bb505f639dbcad2b788db62d6084c2cb4e884bec | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.43e-03 | 157 | 21 | 2 | dd08dc19d434e94a194076c462ee273c682abf55 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.43e-03 | 157 | 21 | 2 | 70fd6c46db4250c7de5c4686a9500689402737f6 | |
| ToppCell | facs-Lung-EPCAM-3m-Myeloid-Nonclassical_Monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.46e-03 | 158 | 21 | 2 | b0508a600994090c6aafd8d779437190a33ad821 | |
| ToppCell | facs-Lung-3m-Hematologic-myeloid-intermediate_monocyte-intermediate_monocyte_l4|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.46e-03 | 158 | 21 | 2 | 7bd4a64a610eb1cbcd3d07ea5258a55107cf6c00 | |
| ToppCell | facs-Lung-3m-Hematologic-myeloid-intermediate_monocyte|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.46e-03 | 158 | 21 | 2 | b35bab2b93d0af821bfae18a358eb7dddaf3860f | |
| ToppCell | facs-Lung-EPCAM-3m-Myeloid-non-classical_monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.46e-03 | 158 | 21 | 2 | a816cc095452308d06f87b77467e2a8c6361fd2a | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.49e-03 | 159 | 21 | 2 | 7ed659163f45e0c4df4782997c0786900c8186c8 | |
| ToppCell | PND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD8_T-CD8_T_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.49e-03 | 159 | 21 | 2 | 8d958d79f5eb3ab683d1245ae7f4f22a2cefbc55 | |
| ToppCell | wk_20-22-Mesenchymal-Myofibro_&_SMC-Myofibro_1|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 2.52e-03 | 160 | 21 | 2 | 5cd4fbbd2ce671a8377416eff94041a111375dee | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-3_VIP_ACHE|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.52e-03 | 160 | 21 | 2 | 903727c14e370e5705394240f0ef61fe3e0a4c25 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.52e-03 | 160 | 21 | 2 | 1e210e526ea4d84fc58a798a26c0929bcb69fd89 | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-Plasma_cells-IgA_plasma_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.52e-03 | 160 | 21 | 2 | e44b3c74c76b4632ada7f5bd6d09434b02d79743 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_prolif|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.56e-03 | 161 | 21 | 2 | 82ed45f144a07856fe92d37426c5f92e259a03a9 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.56e-03 | 161 | 21 | 2 | da9eecf919866a9c579d7a707a996cf335213134 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-H_(AT1)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.56e-03 | 161 | 21 | 2 | d431625c32f59a6b552191f3adc5198bd16ad5cf | |
| ToppCell | E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Mature_Fibroblast_1|E16.5-samps / Age Group, Lineage, Cell class and subclass | 2.62e-03 | 163 | 21 | 2 | f1ec2625b52664308968b01d8e0275e1e0751480 | |
| ToppCell | Immune_cells-T_cells|World / Lineage and Cell class | 2.62e-03 | 163 | 21 | 2 | c5afdb5e7700bbd3ee8276910f9c4b4b3bcc3266 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-4_VIP_DSEL|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.65e-03 | 164 | 21 | 2 | 4baba91f9f734976aef9db2822ff8683b26ea155 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.65e-03 | 164 | 21 | 2 | 43045879505774ac0d9b7f760557955564f06d00 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-epithelial_progenitor_cell-Distal_progenitor|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.65e-03 | 164 | 21 | 2 | d6f71d804bb65301c02ea4e6673e20688b5fcd5b | |
| ToppCell | facs-Liver-Liver_non-hepato/SCs_st-18m-Lymphocytic-T_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.65e-03 | 164 | 21 | 2 | 1a9b444d2c6abcc83d4355ec5228b27541df2bd0 | |
| ToppCell | Globus_pallidus-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.68e-03 | 165 | 21 | 2 | 570483b43ccb5831feec9337b4664814431d40b1 | |
| ToppCell | Globus_pallidus-Endothelial-ENDOTHELIAL_TIP|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.68e-03 | 165 | 21 | 2 | 2026a9a07f4d314cc05c167e491312b373468e46 | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.68e-03 | 165 | 21 | 2 | 4e13fccd32029e2879e85f8966e582a46c09e4aa | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.71e-03 | 166 | 21 | 2 | ceb0a48c0d853448fd45ac31dde046df9a178571 | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-Exhausted_Tfh|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 2.71e-03 | 166 | 21 | 2 | c73fce59256ad501864f44f76cfae2fc33b3777e | |
| ToppCell | facs-Heart-RA-18m-Lymphocytic-B_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-03 | 166 | 21 | 2 | fc2cf67311c86fda75b35fcd4768b6f6f14c59d0 | |
| ToppCell | facs-Heart-RA-18m-Lymphocytic-B_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-03 | 166 | 21 | 2 | 33a6876d06e26176135a73a77c19e634ec53f7ce | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.75e-03 | 167 | 21 | 2 | fe3338f99f94c0dac37e3d649dfdce82e4a56022 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.75e-03 | 167 | 21 | 2 | b4ef07117d14da3d5fbced949e4dfcb01c392295 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.75e-03 | 167 | 21 | 2 | 94fc7df7ca55cd722a8dbd153201a29891217473 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.75e-03 | 167 | 21 | 2 | eff3723fe60755272eca237459165e436e919ece | |
| ToppCell | TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-4|TCGA-Lung / Sample_Type by Project: Shred V9 | 2.78e-03 | 168 | 21 | 2 | aefea14b8b1c1b6a05f827effd22ba15274fddc9 | |
| Drug | Wy-14,643 | 1.73e-07 | 286 | 21 | 6 | CID000005694 | |
| Drug | LG 100268 | 1.73e-06 | 26 | 21 | 3 | ctd:C095104 | |
| Drug | AC1NNF4R | 3.97e-06 | 34 | 21 | 3 | CID005067795 | |
| Drug | DR-0 | 4.34e-06 | 35 | 21 | 3 | CID010062716 | |
| Drug | Tannins | 4.73e-06 | 36 | 21 | 3 | CID000250395 | |
| Drug | Wedelin | 4.86e-06 | 4 | 21 | 2 | CID000181970 | |
| Drug | tyrphostin AG1296 | 8.74e-06 | 44 | 21 | 3 | CID000002049 | |
| Drug | 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | 1.37e-05 | 51 | 21 | 3 | ctd:C038864 | |
| Drug | HCCA | 1.82e-05 | 56 | 21 | 3 | CID000000584 | |
| Drug | ecdysone | 1.95e-05 | 178 | 21 | 4 | CID000019212 | |
| Drug | Suxibuzone [27470-51-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.84e-05 | 196 | 21 | 4 | 6065_DN | |
| Drug | Clorgyline hydrochloride [17780-75-5]; Up 200; 13uM; HL60; HG-U133A | 2.84e-05 | 196 | 21 | 4 | 1604_UP | |
| Drug | Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 2.90e-05 | 197 | 21 | 4 | 6106_DN | |
| Drug | U 0126 | 4.34e-05 | 444 | 21 | 5 | ctd:C113580 | |
| Drug | AC1L1KPQ | 4.92e-05 | 78 | 21 | 3 | CID000005602 | |
| Drug | chikusetsusaponin V | 7.32e-05 | 14 | 21 | 2 | CID000160238 | |
| Drug | grifolin | 1.09e-04 | 17 | 21 | 2 | CID005372312 | |
| Drug | carbamylhydrazine | 1.23e-04 | 18 | 21 | 2 | ctd:C010059 | |
| Drug | AC1L1HD4 | 1.68e-04 | 21 | 21 | 2 | CID000004079 | |
| Drug | TAAD | 1.68e-04 | 21 | 21 | 2 | CID000133445 | |
| Drug | clofibrate | 1.70e-04 | 311 | 21 | 4 | CID000002796 | |
| Drug | Am 580 | 1.73e-04 | 119 | 21 | 3 | ctd:C068073 | |
| Drug | AC1L22KT | 2.03e-04 | 23 | 21 | 2 | CID000013832 | |
| Drug | heptachlor | 2.19e-04 | 129 | 21 | 3 | CID000003589 | |
| Drug | 1nfx | 2.21e-04 | 24 | 21 | 2 | CID000447361 | |
| Drug | docetaxel | 2.40e-04 | 133 | 21 | 3 | ctd:C067311 | |
| Drug | Garcinia Gb2 | 2.40e-04 | 25 | 21 | 2 | CID000161259 | |
| Drug | androstenol | 2.80e-04 | 27 | 21 | 2 | CID000101989 | |
| Drug | SU11274 | 2.80e-04 | 27 | 21 | 2 | CID009549297 | |
| Drug | Farnesol | 2.80e-04 | 27 | 21 | 2 | ctd:D005204 | |
| Drug | testosterone undecanoate | 2.80e-04 | 27 | 21 | 2 | CID000065157 | |
| Drug | Deoxycholic Acid | 2.85e-04 | 141 | 21 | 3 | ctd:D003840 | |
| Drug | LY 171555 | 2.91e-04 | 142 | 21 | 3 | CID000001257 | |
| Drug | AC1O3MFW | 3.02e-04 | 28 | 21 | 2 | CID006332187 | |
| Drug | salbutamol | 3.16e-04 | 146 | 21 | 3 | CID000002083 | |
| Drug | 3-aminobenzamide | 3.47e-04 | 30 | 21 | 2 | ctd:C025160 | |
| Drug | RODAN | 3.47e-04 | 30 | 21 | 2 | CID000076336 | |
| Drug | lindane | 3.69e-04 | 154 | 21 | 3 | CID000000727 | |
| Drug | Dimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; HL60; HT_HG-U133A | 3.91e-04 | 157 | 21 | 3 | 3141_UP | |
| Drug | AC1L1AJ8 | 3.95e-04 | 32 | 21 | 2 | CID000001011 | |
| Drug | ICI 118551 | 3.95e-04 | 32 | 21 | 2 | ctd:C026777 | |
| Drug | NSC49080 | 4.20e-04 | 33 | 21 | 2 | CID000002192 | |
| Drug | GW9662 | 4.36e-04 | 163 | 21 | 3 | CID000644213 | |
| Drug | amobarbital | 4.47e-04 | 34 | 21 | 2 | CID000002163 | |
| Drug | Retinoids | 4.47e-04 | 34 | 21 | 2 | ctd:D012176 | |
| Drug | Garcinia Gb1 | 4.47e-04 | 34 | 21 | 2 | CID000161087 | |
| Drug | Flurandrenolide [1524-88-5]; Up 200; 9.2uM; HL60; HT_HG-U133A | 5.73e-04 | 179 | 21 | 3 | 2184_UP | |
| Drug | 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline | 6.19e-04 | 40 | 21 | 2 | ctd:C088860 | |
| Drug | SureCN160413 | 6.19e-04 | 40 | 21 | 2 | CID011446521 | |
| Drug | Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; PC3; HT_HG-U133A | 6.50e-04 | 187 | 21 | 3 | 7402_DN | |
| Drug | melatonin | 6.51e-04 | 443 | 21 | 4 | CID000000896 | |
| Drug | Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; MCF7; HT_HG-U133A | 7.13e-04 | 193 | 21 | 3 | 6809_UP | |
| Drug | Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A | 7.13e-04 | 193 | 21 | 3 | 7385_UP | |
| Drug | Primal | 7.15e-04 | 43 | 21 | 2 | CID001549157 | |
| Drug | Paroxetine | 7.15e-04 | 43 | 21 | 2 | ctd:D017374 | |
| Drug | Fillalbin [4540-25-4]; Up 200; 13.8uM; PC3; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 4092_UP | |
| Drug | Pentolinium bitartrate [52-62-0]; Up 200; 7.4uM; PC3; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 3676_UP | |
| Drug | Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Up 200; 6.4uM; PC3; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 2096_UP | |
| Drug | Repaglinide [135062-02-1]; Up 200; 8.8uM; HL60; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 6135_UP | |
| Drug | Karakoline [39089-30-0]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 4763_UP | |
| Drug | Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 6824_UP | |
| Drug | Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 3847_UP | |
| Drug | rottlerin; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 7.45e-04 | 196 | 21 | 3 | 825_UP | |
| Drug | Chlorphensin carbamate [886-74-8]; Down 200; 16.2uM; HL60; HG-U133A | 7.45e-04 | 196 | 21 | 3 | 1432_DN | |
| Drug | alpha-estradiol; Down 200; 0.01uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 6169_DN | |
| Drug | Finasteride [98319-26-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 4766_UP | |
| Drug | Carbenoxolone disodium salt [7421-40-1]; Up 200; 6.6uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 3014_UP | |
| Drug | 0393-0188; Down 200; 10uM; PC3; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 7536_DN | |
| Drug | Ciprofloxacin hydrochloride [93107-08-5]; Down 200; 10.8uM; HL60; HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2022_DN | |
| Drug | Hecogenin [467-55-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 3457_UP | |
| Drug | Hymecromone [90-33-5]; Up 200; 22.8uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 5684_UP | |
| Drug | Trifluoperazine dihydrochloride [440-17-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 7420_DN | |
| Drug | Hymecromone [90-33-5]; Down 200; 22.8uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 3045_DN | |
| Drug | Sulfasalazine [599-79-1]; Up 200; 10uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 5446_UP | |
| Drug | Pronethalol hydrochloride [51-02-5]; Up 200; 15uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 2902_UP | |
| Drug | Ceftazidime pentahydrate [78439-06-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 5473_UP | |
| Drug | Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 5615_UP | |
| Drug | Vitexin [3681-93-4]; Down 200; 9.2uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 2155_DN | |
| Drug | rosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 6992_UP | |
| Drug | Thiocolchicoside [602-41-5]; Up 200; 7uM; PC3; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 5095_UP | |
| Drug | Nafcillin sodium salt monohydrate [7177-50-6]; Up 200; 8.8uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 2983_UP | |
| Drug | wortmannin from Penicillium funiculosum; Down 200; 0.01uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 6202_DN | |
| Drug | N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Up 200; 25.2uM; HL60; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 2176_UP | |
| Drug | Piperine [94-62-2]; Up 200; 14uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 4830_UP | |
| Drug | CP-320650-01 [172079-28-6]; Up 200; 1uM; MCF7; HT_HG-U133A | 7.68e-04 | 198 | 21 | 3 | 3908_UP | |
| Drug | Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; PC3; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 6699_UP | |
| Drug | Sulfanilamide [63-74-1]; Up 200; 23.2uM; MCF7; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 3449_UP | |
| Drug | Sulfabenzamide [127-71-9]; Down 200; 14.4uM; PC3; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 6634_DN | |
| Drug | beta- Belladonnine dichloroethylate [191355-47-2]; Up 200; 6uM; MCF7; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 4984_UP | |
| Drug | Lisinopril [83915-83-7]; Down 200; 9uM; MCF7; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 7403_DN | |
| Drug | Coralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 2652_UP | |
| Drug | Piromidic acid [19562-30-2]; Up 200; 13.8uM; HL60; HT_HG-U133A | 7.79e-04 | 199 | 21 | 3 | 2996_UP | |
| Drug | Isosorbide dinitrate [87-33-2]; Up 200; 17uM; MCF7; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 6038_UP | |
| Drug | Eucatropine hydrochloride [536-93-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 3935_UP | |
| Drug | Nadolol [42200-33-9]; Up 200; 13uM; HL60; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 3020_UP | |
| Drug | Halofantrine hydrochloride [36167-63-2]; Up 200; 7.4uM; MCF7; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 6509_UP | |
| Drug | Methyl benzethonium chloride [25155-18-4]; Up 200; 8.6uM; HL60; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 2190_UP | |
| Drug | Famprofazone [22881-35-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 7.90e-04 | 200 | 21 | 3 | 6029_UP | |
| Drug | AC1L1F9Q | 8.02e-04 | 201 | 21 | 3 | CID000003144 | |
| Drug | AC1L8YDS | 8.54e-04 | 47 | 21 | 2 | CID000389644 | |
| Disease | connective tissue disease (implicated_via_orthology) | 1.18e-06 | 3 | 19 | 2 | DOID:65 (implicated_via_orthology) | |
| Disease | hypertension (biomarker_via_orthology) | 1.21e-05 | 227 | 19 | 4 | DOID:10763 (biomarker_via_orthology) | |
| Disease | Neoplasm of the genitourinary tract | 1.08e-04 | 24 | 19 | 2 | cv:C0042065 | |
| Disease | systemic scleroderma (is_implicated_in) | 1.08e-04 | 24 | 19 | 2 | DOID:418 (is_implicated_in) | |
| Disease | Sezary Syndrome | 1.37e-04 | 27 | 19 | 2 | C0036920 | |
| Disease | Endometrioma | 1.45e-04 | 161 | 19 | 3 | C0269102 | |
| Disease | Endometriosis | 1.45e-04 | 161 | 19 | 3 | C0014175 | |
| Disease | liver cirrhosis (biomarker_via_orthology) | 2.18e-04 | 34 | 19 | 2 | DOID:5082 (biomarker_via_orthology) | |
| Disease | Male sterility | 4.35e-04 | 48 | 19 | 2 | C0917731 | |
| Disease | Male infertility | 4.35e-04 | 48 | 19 | 2 | C0021364 | |
| Disease | Subfertility, Male | 4.35e-04 | 48 | 19 | 2 | C0848676 | |
| Disease | breast carcinoma (is_marker_for) | 8.22e-04 | 66 | 19 | 2 | DOID:3459 (is_marker_for) | |
| Disease | Liver Dysfunction | 9.77e-04 | 72 | 19 | 2 | C0086565 | |
| Disease | Liver diseases | 9.77e-04 | 72 | 19 | 2 | C0023895 | |
| Disease | Hodgkins lymphoma | 1.27e-03 | 82 | 19 | 2 | EFO_0000183 | |
| Disease | congestive heart failure (is_marker_for) | 1.27e-03 | 82 | 19 | 2 | DOID:6000 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TMYNQCMEVGYKKCM | 221 | O60507 | |
| SGFMLMKNCMDVDEC | 1061 | Q75N90 | |
| GKDCIMHGYMSKMGN | 556 | P25098 | |
| DQIMMCSMYGICKVK | 701 | P06400 | |
| FCRLKKCLEMGMKME | 171 | P49116 | |
| VMACMEYEMGKKKCE | 126 | Q9Y2R2 | |
| YKCKNGGNCVMDMYM | 171 | Q96RI1 | |
| KCKEMGMLAECMYTG | 196 | Q96RI1 | |
| LLMYCAKMEKDGYGM | 201 | Q96JP0 | |
| KDEDMYGTMKKMICC | 296 | Q9UBY5 | |
| GCAGKYIAMVMMKAI | 436 | P11511 | |
| KCDEGYESGFMMMKN | 1096 | P35555 | |
| GKAMYKGMIDCLMKT | 41 | Q9H1K4 | |
| MGLKMSCLKGFQMCV | 1 | Q96GX8 | |
| EKFPCMCGMLHSKTM | 361 | P28476 | |
| DSFMKMLRSKMGKCC | 51 | B2RU33 | |
| QACIMKMVCGKAMTD | 311 | P03999 | |
| DSFMKMLRSKMGKCC | 51 | Q86YR6 | |
| EKQKMYMVMEYCVCG | 121 | Q15831 | |
| EMKCCANLTGGYMVM | 361 | Q15437 | |
| LYECCPGYMRMEGMK | 76 | Q15063 | |
| AKCMFFKDKTMLCPM | 5121 | O14686 |